Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08 Setembro 2023 - 9:00AM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that Mike Raab, president and chief executive
officer of Ardelyx, will present at the H.C. Wainwright 25th
Annual Global Investment Conference on Monday, September 11, 2023,
at 12:00 p.m. ET in New York City.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 30 days
following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and
commercialize innovative, first-in-class medicines that meet
significant unmet medical needs. Ardelyx’s first approved product,
IBSRELA® (tenapanor) is available in the United States and Canada.
Ardelyx is developing XPHOZAH® (tenapanor), a novel product
candidate for the control of serum phosphorus in adult patients
with chronic kidney disease (CKD) on dialysis who have had an
inadequate response or intolerance to phosphate binder therapy,
which has completed three successful Phase 3 trials and an
additional two Phase 4 open label trials. Ardelyx has a Phase 2
potassium lowering compound, RDX013, for the potential treatment of
elevated serum potassium, or hyperkalemia, a problem among certain
patients with kidney and/or heart disease and an early-stage
program in metabolic acidosis, a serious electrolyte disorder in
patients with CKD. Ardelyx has established agreements with Kyowa
Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in
Canada for the development and commercialization of tenapanor in
their respective territories.For more information, please visit
https://ardelyx.com/ and connect with us on X (Formerly Twitter),
LinkedIn and Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Kimia Keshtbod kkeshtbod@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024